{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary+Hyperparathyroidism%2C+Chronic+Kidney+Disease",
    "query": {
      "condition": "Secondary Hyperparathyroidism, Chronic Kidney Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 67,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary+Hyperparathyroidism%2C+Chronic+Kidney+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T14:57:41.605Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00888069",
      "title": "Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Secondary Hyperparathyroidism",
        "Chronic Renal Insufficiency",
        "Chronic Renal Failure"
      ],
      "interventions": [
        {
          "name": "CTAP101 Capsules",
          "type": "DRUG"
        },
        {
          "name": "CTAP101 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO IP Holdings II, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 28,
      "start_date": "2009-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 12,
      "location_summary": "Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Brooklyn Center",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00888069"
    },
    {
      "nct_id": "NCT00108394",
      "title": "Osteopenia and Renal Osteodystrophy: Evaluation and Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteopenia",
        "Renal Osteodystrophy"
      ],
      "interventions": [
        {
          "name": "pamidronate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-10",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2009-01-21",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108394"
    },
    {
      "nct_id": "NCT05836220",
      "title": "Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "End Stage Kidney Disease"
      ],
      "interventions": [
        {
          "name": "PLS240",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Open-Label Extension PLS240",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pathalys Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 412,
      "start_date": "2023-05-15",
      "completion_date": "2025-08-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 50,
      "location_summary": "Anaheim, California • Chula Vista, California • Escondido, California + 43 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05836220"
    },
    {
      "nct_id": "NCT03588884",
      "title": "Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism Due to Renal Causes",
        "Vitamin D Insufficiency",
        "CKD Stage 3",
        "CKD Stage 4"
      ],
      "interventions": [
        {
          "name": "Calcifediol Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Calcifediol Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Cholecalciferol",
          "type": "DRUG"
        },
        {
          "name": "Paricalcitol Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2018-06-08",
      "completion_date": "2020-04-24",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 3,
      "location_summary": "Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03588884"
    },
    {
      "nct_id": "NCT00781417",
      "title": "Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Atlanta VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 48,
      "start_date": "2008-10",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-07",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00781417"
    },
    {
      "nct_id": "NCT02341417",
      "title": "Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism, Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Cinacalcet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 28,
      "start_date": "2015-06-10",
      "completion_date": "2017-03-15",
      "has_results": true,
      "last_update_posted_date": "2020-06-29",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Tucker, Georgia • Baltimore, Maryland + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tucker",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02341417"
    },
    {
      "nct_id": "NCT01100723",
      "title": "Trial to Optimize Mineral Outcomes in Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Cinacalcet, active vitamin D analogue",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2010-03",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 1,
      "location_summary": "Lynchburg, Virginia",
      "locations": [
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100723"
    },
    {
      "nct_id": "NCT01896232",
      "title": "Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Etelcalcetide",
          "type": "DRUG"
        },
        {
          "name": "Cinacalcet",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 683,
      "start_date": "2013-08-13",
      "completion_date": "2015-01-08",
      "has_results": true,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 41,
      "location_summary": "Azusa, California • Bakersfield, California • Chula Vista, California + 37 more",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896232"
    },
    {
      "nct_id": "NCT00792857",
      "title": "Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Secondary Hyperparathyroidism",
        "Chronic Renal Insufficiency",
        "Chronic Renal Failure"
      ],
      "interventions": [
        {
          "name": "CTAP201 Injection",
          "type": "DRUG"
        },
        {
          "name": "Doxercalciferol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO IP Holdings II, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-11",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2014-09-29",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 6,
      "location_summary": "Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00792857"
    },
    {
      "nct_id": "NCT01290029",
      "title": "Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Hyperparathyroidism, Secondary",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Cinacalcet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "2190 Days",
        "sex": "ALL",
        "summary": "28 Days to 2190 Days"
      },
      "enrollment_count": 14,
      "start_date": "2011-01-25",
      "completion_date": "2015-09-23",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-07-23T14:57:41.605Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290029"
    }
  ]
}